Key result
Sotagliflozin improves ventricular function and metabolism in diabetic mice despite persistent obesity and insulin resistance.
Why the study?
Sotagliflozin improves cardiovascular outcomes in patients with diabetes and heart failure, but the metabolic mechanisms underlying these benefits remain incompletely defined.
Does sotagliflozin improve cardiac function and metabolism in a mouse model of type 2 diabetes?
Does sotagliflozin improve cardiac function and metabolism in a mouse model of type 2 diabetes?
Dual SGLT1/2 inhibition with sotagliflozin induces selective cardiac metabolic remodeling and improves ventricular function in diabetic cardiomyopathy independent of global metabolic correction.
Answers are grounded in this paper and cite their sources.
Sotagliflozin effects in diabetic mice do not alter practice; hypothesis-generating for dual SGLT1/2 mechanisms in cardiomyopathy.
Sotagliflozin (SOTA), a dual sodium-glucose cotransporter (SGLT)1/2 inhibitor, improves cardiovascular outcomes in patients with diabetes and heart failure, yet the metabolic mechanisms underlying these benefits remain incompletely defined. As a model of type 2 diabetes, db/db mice were treated with SOTA (5 mg/kg/day) in drinking water for 4 weeks. Cardiac metabolism was assessed using LC-MS/MS, cardiac function by echocardiography, and susceptibility to ischemia/reperfusion injury in Langendorff-perfused hearts. Systemic metabolism was characterised by plasma biochemical profiling and 1 H NMR spectroscopy of peripheral tissues. db/db mice exhibited obesity, hyperglycaemia, hyperinsulinaemia, and diastolic dysfunction, alongside perturbed cardiac and systemic metabolism. SOTA treatment improved hyperglycaemia, ventricular function and cardiac metabolomic profile without correcting obesity or insulin resistance. In the heart, SOTA partially restored glycolytic intermediates and improved bioenergetics, whereas systemic metabolic abnormalities largely persisted. These findings suggest dual SGLT1/2 inhibition induces selective cardiac metabolic remodelling in diabetic cardiomyopathy independent of global metabolic correction.
No takes yet. Share an insight, caveat, or question.
Young et al. (2026) studied Type 2 diabetes and diabetic cardiomyopathy (n=40). Sotagliflozin vs. Untreated db/db mice was evaluated on Cardiac function and metabolism (echocardiography and metabolomic profiling). Sotagliflozin treatment in type 2 diabetic mice improved hyperglycemia, ventricular function, and the cardiac metabolomic profile, despite persistent systemic obesity and insulin resistance.
Synapse has enriched 10 related papers. Consider them for comparative context: